Shares of Moderna Inc. MRNA,
rose 1.3% in premarket trade on Monday after the company said it planned to launch new development programs using its mRNA technology that will focus on the development of seasonal flu, HIV and Nipah virus. This follows the success of the COVID-19 mRNA vaccine, which is one of two vaccines authorized so far by the US CEO. Moderna also said she plans to expand her respiratory syncytial virus to include older adults and plans to try different vaccines. combinations fighting influenza, COVID-19, RSV and human metapneumovirus. “The year 2020, which has posed a unique challenge for the whole society, has proved to be an extraordinary period of proof of concept for Moderna,” CEO Stéphane Bancel said in a press release. As part of its corporate upgrade, Moderna said it had about $ 5 billion in cash as of December 31, compared to the $ 1.2 billion in cash it had at the same time a year ago, and expects to generate revenue from ‘at least $ 11.7 billion. in 2021 for its COVID-19 vaccine based on advance purchase agreements. Shares of Moderna have risen 489.1% over the past year, while the S&P 500 SPX,
increases by 19.7%.